Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor suppressor genotype influences the extent and mode of immunosurveillance in lung cancer.

Nature communications·2026
Same author

Deficiency in POLE Exonuclease Causes Synthetic Lethality in Highly Aneuploid Cancer Cells.

Cancer research·2026
Same author

GLYATL1 is associated with metabolic and epigenetic changes and with endocrine resistance in luminal breast cancer.

Clinical epigenetics·2026
Same author

A Roadmap to Transform Lung Cancer Outcomes: Priorities in Biology, Therapeutic Innovation, Early Detection, Prevention, and Interception.

Cancer discovery·2026
Same author

Clinicogenomic Landscape and Function of <i>PIK3CA</i>, <i>AKT1</i>, and <i>PTEN</i> Mutations in Breast Cancer.

JCO precision oncology·2026
Same author

The Pan-Tumor Landscape of Gene Amplifications and Copy Number Amplification Ratio for Established and Emerging Clinical Targets.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Type II JAK2 Inhibitor Gets Off to a Strong Start.

Cancer discovery·2026
Same journal

Pancreatic Cancer: Translating Tumor Biology into Actionability.

Cancer discovery·2026
Same journal

Reconsidering Cancer Therapy through the Lens of Biomolecular Condensates.

Cancer discovery·2026
Same journal

The Promise of Machine Learning-Based Population Screening for Hepatocellular Carcinoma.

Cancer discovery·2026
Same journal

Spatially Resolved Proteomic Cartography Illuminates the Earliest Molecular Programs in Pancreatic Cancer Evolution.

Cancer discovery·2026
Same journal

Oral Regimens for AML Make Strides.

Cancer discovery·2026
See all related articles

Related Experiment Video

Updated: May 25, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.0K

EML4-ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis.

Alberto Diaz-Jimenez1,2, Emily G Shuldiner3, Kalman Somogyi1

  • 1Division of Molecular Thoracic Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Cancer Discovery
|September 23, 2025
PubMed
Summary
This summary is machine-generated.

Echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion variants drive lung cancer differently. These distinct oncogenic drivers impact tumor-suppressor gene effects and therapeutic responses, challenging uniform treatment approaches.

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.6K
The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues
07:39

The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues

Published on: June 16, 2018

9.8K

Related Experiment Videos

Last Updated: May 25, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.0K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.6K
The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues
07:39

The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues

Published on: June 16, 2018

9.8K

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Diverse echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions are key drivers in lung adenocarcinoma.
  • Existing research lacks understanding of functional differences between EML4-ALK variants, despite distinct breakpoints.

Purpose of the Study:

  • To investigate the functional distinctions between EML4-ALK variants in lung cancer.
  • To determine if EML4-ALK variants exhibit variant-specific interactions with tumor-suppressor genes.
  • To explore the implications of EML4-ALK variant diversity on therapeutic strategies.

Main Methods:

  • Somatic genome editing was employed to create autochthonous mouse models of EML4-ALK-driven lung tumors.
  • Multiplexed genome editing quantified the impact of 29 putative tumor-suppressor genes on EML4-ALK variant-driven cancer growth.
  • Pharmacogenomic analyses and examination of human lung cancer genomic landscapes were performed.

Main Results:

  • Echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) variant 3 (V3) demonstrated greater oncogenicity than variant 1 (V1).
  • Numerous tumor-suppressor genes exhibited variant-specific effects on tumorigenesis driven by EML4-ALK V1 and V3.
  • Tumor genotype was found to influence therapeutic responses, and variant-specific genomic differences were observed in human cancers.

Conclusions:

  • EML4-ALK variants function as distinct oncogenes, not a uniform entity.
  • Oncogenic fusion partner protein diversity and tumor-suppressor gene alterations significantly impact cancer biology.
  • Findings suggest personalized treatment approaches may be necessary for EML4-ALK-driven lung cancers based on specific variant.